Xeris is developing its pipeline both through internal clinical development and external partnerships to advance the commercial potential of its products globally.
Xeris is interested in establishing a portfolio of strategic collaborations with key partners who wish to codevelop products using Xeris’ platform technologies (XeriSol™ and XeriJect™).
Currently, Xeris is working on a number of formulation feasibility programs in the areas of peptides, vaccines, and monoclonal antibodies.
We welcome the opportunity to discuss areas of potential common interest from which to build value for both parties.
To discuss partnering opportunities, please contact us.
Xeris Biopharma is excited to announce approval for a new product, furthering our commitment to improving more patient's lives. Read More
Xeris has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms.
Find out more
Gvoke® (glucagon injection)